Testing new drugs for relapsed ewing sarcoma and related tumors
Part of Cancer clinical trials.
This study is testing new drugs for young people (ages 10 and up) with Ewing sarcoma or related tumors that have come back or stopped responding to treatment. The goal is to find promising drugs that may help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 10 years or older.
- Your cancer (Ewing sarcoma, desmoplastic small round cell tumor, or sarcoma) must have come back or not responded to previous treatment.
- You must have already tried at least 2 standard chemotherapy treatments.
- The tumor must be at least 1 cm (about the size of a pea) and measurable on a scan.
- You must be in generally good physical condition (able to be up and about, even if you need some rest).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, KC1036, for adolescents with advanced Ewing sarcoma that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow the cancer.
This trial is testing a new drug called xaluritamig for children, teens, and adults with Ewing sarcoma that has come back or is not responding to treatment. The goal is to see if this drug can shrink the cancer or stop it from growing.
This trial tests a personalized radiation therapy that adjusts the dose based on your tumor. It aims to improve treatment for Ewing sarcoma while limiting side effects.
This trial tests lurbinectedin, a cancer medicine, by itself (no other drugs) in children and young adults whose Ewing sarcoma has come back or did not respond to prior treatment. It aims to see how safe the drug is and whether it can help control the cancer.
This trial tests a new type of immunotherapy that targets a specific genetic change in Ewing sarcoma and a related rare tumor called DSRCT. It may be an option for patients whose cancer has come back, spread, or is very high-risk after standard chemotherapy.
This study is testing whether a blood test called ProGRP can help doctors see how well treatment is working in people with Ewing sarcoma. If you are newly diagnosed and are about to start your first treatment, this study may help improve how we track your progress.
Hear when a new Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.